➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
Johnson and Johnson
Merck
McKesson

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROXOCOBALAMIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Hydroxocobalamin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01147289 ↗ Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain Completed Eurofarma Laboratorios S.A. Phase 3 2011-02-01 A phase III, randomized, multicenter, open label clinical trial to evaluate efficacy and safety of the injectable association of dexamethasone, dipyrone, and hydroxocobalamin in lumbar sciatic pain. The study will enroll 140 patients in each arm (280 total).
NCT01656616 ↗ Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis Unknown status Maine Medical Center N/A 2012-08-01 The costs to a rural emergency medical services (EMS) system of a change from a traditional cyanide antidote kit to a kit containing hydroxocobalamin alone are currently unknown. The purpose of this study is to use current EMS data to calculate the costs to a rural EMS system associated with the adoption of a hydroxocobalamin protocol for the treatment of suspected cyanide exposure.
NCT03446599 ↗ Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery Not yet recruiting Dartmouth-Hitchcock Medical Center Phase 2 2018-11-01 This is a pilot study to determine the hemodynamic effects when hydroxocobalamin vs methylene blue is administered during cardiopulmonary bypass in patients at risk of vasoplegia by measuring mean arterial pressure (MAP), systemic vascular resistance (SVR) and vasopressor requirement.
NCT03735316 ↗ Vitamin B12a Vasoplegic Syndrome Recruiting Mayo Clinic Phase 2 2018-11-02 The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.
NCT03783091 ↗ A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock Not yet recruiting Medical College of Wisconsin Phase 2 2019-07-01 This study will randomize 30 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to reduce vasopressor dose at 3 hours.
NCT04054999 ↗ [Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients] Not yet recruiting Mayo Clinic Phase 4 2019-08-12 This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
NCT04150042 ↗ Intravenous Melphalan, BCNU, Vitamin B12b, Vitamin C, Ethanol, and Stem Cell Infusion in Pancreatic Cancer With an Inherited BRCA Mutation Not yet recruiting General Oncology, Inc. Phase 2 2020-03-01 The study is a phase 2A, single-arm trial that will evaluate the effectiveness and safety of the investigational treatment on oligometastatic pancreatic cancer following resection of the primary tumor in patients who have an inherited, deleterious BRCA1 or BRCA2 genetic alteration. The investigational treatment will involve 2 (and possibly 3) cycles of a combination of intravenous: melphalan, BCNU, low-dose ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed for vitamin C.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Hydroxocobalamin

Condition Name

Condition Name for Hydroxocobalamin
Intervention Trials
Vasoplegic Syndrome 2
Pancreatic Adenocarcinoma Metastatic 1
Cardiac Surgery Using Cardiopulmonary Bypass 1
Lumbar Sciatic Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Hydroxocobalamin
Intervention Trials
Vasoplegia 3
Syndrome 2
Colitis, Ulcerative 1
Poisoning 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Hydroxocobalamin

Trials by Country

Trials by Country for Hydroxocobalamin
Location Trials
United States 5
Brazil 3
Saudi Arabia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Hydroxocobalamin
Location Trials
Massachusetts 1
Florida 1
Minnesota 1
New Hampshire 1
Maine 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Hydroxocobalamin

Clinical Trial Phase

Clinical Trial Phase for Hydroxocobalamin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Hydroxocobalamin
Clinical Trial Phase Trials
Not yet recruiting 6
Unknown status 1
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Hydroxocobalamin

Sponsor Name

Sponsor Name for Hydroxocobalamin
Sponsor Trials
Mayo Clinic 2
Maine Medical Center 1
Dammam University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Hydroxocobalamin
Sponsor Trials
Other 7
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Colorcon
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.